Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) confirms benefit of thulium laser resection (TmLRP) for patients with benign prostatic syndrome (BPS)

Boston Scientific welcomes the G-BA’s recent decision to adopt changes to both the “Methoden vertragsärztlicher Versorgung“ (ambulatory care methods, MVV-RL) and “Methoden Krankenhausbehandlung“ (hospital care methods, KHMe-RL) guidelines for thulium laser resection (TmLRP) for the treatment of benign prostatic syndrome (BPS).

There are several methods of treatment for BPS that are authorized in Germany, transurethral resection of the prostate (TURP), adenectomy, holmium laser resection (HoLRP) and holmium laser enucleation (HoLEP). Prostate resection by means of the thulium laser (TmLRP) procedure is another method for the treatment of BPS and can be deployed as an alternative to the previously mentioned treatment options for patients with an appropriate medical indication.  The laser’s vaporizing effect is used to cut out tissue from the enlarged prostate using a continual stream of energy, rather than the pulsed energy output provided by holmium laser resection.

The text of the G-BA decision and the main justifications are available online on the G-BA website at https://www.g-ba.de/.